Table 1.
Baseline characteristics and conditioning regimen of enrolled patients
| Variable | n | Mean (SD) or % | Median (range) |
| Age (years) | 31 | 35.42 (19.38) | 29 (10–64) |
| <18 years | 8 | 25.8 |
|
| Sex |
|
|
|
| Male | 19 | 61.3 |
|
| Female | 12 | 38.7 |
|
| Diagnosis |
|
|
|
| MM | 11 | 35.5 |
|
| HL | 7 | 22.6 |
|
| AML | 6 | 19.4 |
|
| NHL | 4 | 12.9 |
|
| CML | 1 | 3.2 |
|
| ALL | 1 | 3.2 |
|
| RMS | 1 | 3.2 |
|
| Type of transplant |
|
|
|
| Autogenic | 22 | 71 |
|
| Allogenic | 9 | 29 |
|
| Conditioning regimen |
|
|
|
| High dose melphalan | 12 | 38.7 |
|
| BEAM | 6 | 19.4 |
|
| CBV | 6 | 19.4 |
|
| Flu Mel | 5 | 16.1 |
|
| FLU BU | 1 | 3.2 |
|
| Mel Treo | 1 | 3.2 |
|
| Haemoglobin (g/dL) | 31 | 11.51 (2.17) | 12 (7.4–14.9) |
| Platelets (×103/µL) | 31 | 162 (70.7) | 162 (64–298) |
| TLC (/µL) | 31 | 8952.26 (8246) | 5320 (2100–35800) |
| ANC (/mm3) | 31 | 6119.35 (7773) | 3100 (200–30700) |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BEAM, BCNU, etoposide, ara-C and melphalan; CBV, cyclophosphamide, etoposide, BCNU; CML, chronic myeloid leukaemia; Flu Bu, fludarabine and busulfan; Flu Mel, fludarabine and melphalan; HL, Hodgkin’s Lymphoma; Mel Treo, melphalan and treosulfan; MM, multiple myeloma; NHL, Non-Hodgkin’s Lymphoma; RMS, rhabdomyosarcoma.